Iterum Therapeutics plc (NASDAQ:ITRM) has a beta value of 1.34 and has seen 2,242,679 shares traded in the recent trading session. The company, currently valued at $24.53 Million, closed the recent trade at $1.38 per share which meant it lost -$0.15 on the day or -10.13% during that session. The ITRM stock price is -454.35% off its 52-week high price of $7.65 and 5.8% above the 52-week low of $1.3. If we look at the company’s 10-day average daily trading volume, we find that it stood at 713.08 Million shares traded. The 3-month trading volume is 823.65 Million shares.
The consensus among analysts is that Iterum Therapeutics plc (ITRM) is a Hold stock at the moment, with a recommendation rating of 2.8. 1 analysts rate the stock as a Sell, while none rate it as Overweight. 3 out of 5 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.74.
Iterum Therapeutics plc (NASDAQ:ITRM) trade information
Despite being -10.46% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the ITRM stock price touched $1.66 or saw a rise of 15.74%. Year-to-date, Iterum Therapeutics plc shares have moved -68.92%, while the 5-day performance has seen it change -12.03%. Over the past 30 days, the shares of Iterum Therapeutics plc (NASDAQ:ITRM) have changed -66.78%. Short interest in the company has seen 366.88 Million shares shorted with days to cover at 0.45.
Iterum Therapeutics plc (ITRM) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest -32.4% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Iterum Therapeutics plc (NASDAQ:ITRM)’s Major holders
Insiders own 3.58% of the company shares, while shares held by institutions stand at 70.07% with a share float percentage of 72.67%. Investors are also buoyed by the number of investors in a company, with Iterum Therapeutics plc having a total of 25 institutions that hold shares in the company. The top two institutional holders are Canaan Partners X LLC with over 1.73 Million shares worth more than $4.7 Million. As of March 30, 2020, Canaan Partners X LLC held 11.66% of shares outstanding.
The other major institutional holder is Sofinnova Investments, Inc., with the holding of over 1.73 Million shares as of March 30, 2020. The firm’s total holdings are worth over $4.68 Million and represent 11.61% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd and Destra Inv Tr-Destra Granahan Small Cap Advantage Fd. As of March 30, 2020, the former fund manager holds about 0.93% shares in the company for having 137700 shares of worth $373.17 Thousand while later fund manager owns 783 shares of worth $2.12 Thousand as of March 30, 2020, which makes it owner of about 0.01% of company’s outstanding stock.